Literature DB >> 19782055

Dynorphin, stress, and depression.

Allison T Knoll1, William A Carlezon.   

Abstract

Stress is most often associated with aversive states. It rapidly induces the release of hormones and neuropeptides including dynorphin, which activates kappa opioid receptors (KORs) in the central and peripheral nervous systems. In animal models, many aversive effects of stress are mimicked or exacerbated by stimulation of KORs in limbic brain regions. Although KOR signaling during acute stress may increase physical ability (by producing analgesia) and motivation to escape a threat (by producing aversion), prolonged KOR signaling in response to chronic or uncontrollable stress can lead to persistent expression of behavioral signs that are characteristic of human depressive disorders (i.e., "prodepressive-like" signs). Accumulating evidence suggests that KORs contribute to the progressive amplification (sensitization) of stress-induced behaviors that occurs with repeated exposure to stress. Many of the aversive effects of stress are blocked by KOR antagonists, suggesting that these agents may have potential as therapeutics for stress-related conditions such as depression and anxiety disorders. This review summarizes current data on how KOR systems contribute to the acute (rapid), delayed, and cumulative molecular and behavioral effects of stress. We focus on behavioral paradigms that provide insight on interactions between stress and KOR function within each of these temporal categories. Using a simplified model, we consider the time course and mechanism of KOR-mediated effects in stress and suggest future directions that may be useful in determining whether KOR antagonists exert their therapeutic effects by preventing the development of stress-induced behaviors, the expression of stress-induced behaviors, or both. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782055      PMCID: PMC2819644          DOI: 10.1016/j.brainres.2009.09.074

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  224 in total

Review 1.  Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications.

Authors:  A Mansour; C A Fox; H Akil; S J Watson
Journal:  Trends Neurosci       Date:  1995-01       Impact factor: 13.837

2.  The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation.

Authors:  M G Weisskopf; R A Zalutsky; R A Nicoll
Journal:  Nature       Date:  1993-04-01       Impact factor: 49.962

3.  Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus.

Authors:  J J Wagner; G W Terman; C Chavkin
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

4.  Opioid precursor gene expression in the human hypothalamus.

Authors:  R R Sukhov; L C Walker; N E Rance; D L Price; W S Young
Journal:  J Comp Neurol       Date:  1995-03-20       Impact factor: 3.215

5.  Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats.

Authors:  R Bals-Kubik; A Ableitner; A Herz; T S Shippenberg
Journal:  J Pharmacol Exp Ther       Date:  1993-01       Impact factor: 4.030

6.  Involvement of spinal kappa opioid receptors in a type of footshock induced analgesia in mice.

Authors:  L Menendez; F Andres-Trelles; A Hidalgo; A Baamonde
Journal:  Brain Res       Date:  1993-05-21       Impact factor: 3.252

7.  Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum.

Authors:  R L Cole; C Konradi; J Douglass; S E Hyman
Journal:  Neuron       Date:  1995-04       Impact factor: 17.173

8.  Corticosterone in the range of stress-induced levels possesses reinforcing properties: implications for sensation-seeking behaviors.

Authors:  P V Piazza; V Deroche; J M Deminière; S Maccari; M Le Moal; H Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

9.  Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters.

Authors:  C T Drake; G W Terman; M L Simmons; T A Milner; D D Kunkel; P A Schwartzkroin; C Chavkin
Journal:  J Neurosci       Date:  1994-06       Impact factor: 6.167

10.  Kappa opioids inhibit induction of long-term potentiation in the dentate gyrus of the guinea pig hippocampus.

Authors:  G W Terman; J J Wagner; C Chavkin
Journal:  J Neurosci       Date:  1994-08       Impact factor: 6.167

View more
  214 in total

Review 1.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

2.  Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Authors:  Jermaine D Jones; Rachel R Luba; Jonathan L Vogelman; Sandra D Comer
Journal:  Am J Addict       Date:  2015-12-21

Review 3.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 4.  The molecular and cellular mechanisms of depression: a focus on reward circuitry.

Authors:  Megan E Fox; Mary Kay Lobo
Journal:  Mol Psychiatry       Date:  2019-04-09       Impact factor: 15.992

5.  Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats.

Authors:  Stephanie L Grella; Douglas Funk; Kathy Coen; Zhaoxia Li; A D Lê
Journal:  Behav Brain Res       Date:  2014-02-28       Impact factor: 3.332

6.  Interneurons scratch an itch.

Authors:  Paula Juliana Seadi Pereira; Ethan A Lerner
Journal:  Neuron       Date:  2014-05-07       Impact factor: 17.173

Review 7.  Influence of stress associated with chronic alcohol exposure on drinking.

Authors:  Howard C Becker
Journal:  Neuropharmacology       Date:  2017-04-19       Impact factor: 5.250

Review 8.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

9.  κ Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake.

Authors:  Timothy W Whitfield; Joel E Schlosburg; Sunmee Wee; Adam Gould; Olivier George; Yanabel Grant; Eva R Zamora-Martinez; Scott Edwards; Elena Crawford; Leandro F Vendruscolo; George F Koob
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

10.  Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats.

Authors:  Shayla E Russell; Anna B Rachlin; Karen L Smith; John Muschamp; Loren Berry; Zhiyang Zhao; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.